Announcing a New Clinical Study for PBC Patients Hi Yall, Intercept is now enrolling PBC patients in another study for investigational medicine, obeticholic acid (OCA). Below is a quick overview of the study, and Im hoping members of the PBCers group will participate in this study. This is for all of us, so please help if you can. Thanks, Linie Announcing a New Clinical Study for PBC Patients WHO is conducting this study? WHO is eligible to participate? Intercept Pharmaceuticals is conducting a phase 2 clinical study (number 747-205), of the investigational medicine, obeticholic acid (OCA), in patients with primary biliary cirrhosis (PBC). This study is aiming to enroll up to 25 PBC patients; information on the eligibility criteria is available at clinicaltrials.gov/ct2/show/NCT01865812?term=747-205&rank=1. WHAT is the purpose of this study? The purpose of this study is to learn how OCA impacts the lipid levels in patients who are taking it. Patients who participate in the study will take OCA for eight weeks, come off the treatment for four weeks, and then have the option to resume treatment with OCA for up to two years. WHERE will this study be conducted? This study is being conducted at multiple study centers in the U.S. You can find out more about specific site locations at clinicaltrials.gov/ct2/show/NCT01865812?term=747-205&rank=1. WHEN can patients enroll in this study? The study is enrolling now, with the goal of having all 25 patients enrolled by the end of April 2014. HOW can I learn more about enrolling? Please speak to your healthcare provider to discuss if this clinical study is an appropriate option for you. More information on the study is available at clinicaltrials.gov/ct2/show/NCT01865812?term=747-205&rank=1.
Posted on: Fri, 04 Apr 2014 22:21:46 +0000
Trending Topics
Recently Viewed Topics
© 2015